Tokyo, July 9 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000058402) titled 'Use-result survey to evaluate the safety and outcome of QUVIVIQ use in patients with insomnia' on July 8.
Study Type:
Observational
Primary Sponsor:
Institute - Nxera Pharma Japan Co.,Ltd
Condition:
Condition - insomnia
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - To evaluate the safety and efficacy of QUVIVIQ Tablets 25 mg and QUVIVIQ Tablets 50 mg in patients with insomnia under actual conditions of use.
Basic objectives2 - Safety,Efficacy
Eligibility:
Age-lower limit - Not applicable
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion cri...